Colgate-Palmolive: What we're watching for in 2Q26 results

Research evidence excerpt

Colgate-Palmolive: What we're watching for in 2Q26 results

Deutsche Bank

Research

Rating Company Date

Buy Colgate-Palmolive 16 July 2026

North America Reuters Bloomberg Rating Buy

United States CL.N CL US Price target (USD) 99.00 Price at 15 Jul 26 91.47

52-week range 99.14 – 10.85

Consumer

Consumer Staples Valuation & Risks

What we're watching for in 2Q26 results

Steve Powers

CL reports 2Q26 earnings results on Friday, July 31st pre-market Research Analyst

+1-212-250-5480 Heading into 2Q26 results, our estimates are generally in line with consensus, and

we forecast organic sales growth of +2.6% and diluted EPS of $0.95. Recent Christopher Barnes, CFA

tracked channel data through late June showed a notable acceleration in total Research Analyst

company sales to +5.7% L4W (including Hill's), suggesting at least a partial +1-212-454-0778

recovery from the category softness management highlighted at our June

Nikhil Jain, CFA conference. While this supports a somewhat more constructive read on Research Associate

underlying demand, we leave our forecasts unchanged out of prudence, given +1-212-250-3253

potential noise in the data, differences between retail and wholesale trends, and

timing-related factors. Notably, improvement through the quarter appears to Angeline Goh

have been driven by core categories such as toothpaste (flat in 2Q vs. -3.9% in Research Associate

+1-212-250-4515

1Q) and dish soap (+1.7% vs. -3.7% in 1Q). Outside North America, our forecast

remains grounded but constructive, with organic sales growth of +5.0% in Latin

America and +4.0% in EMEA. As such, we will focus on whether international

momentum remains intact and whether improving U.S. consumption trends can

be sustained into 2H26. We also expect discussion of Hill's fresh pet food launch,